Thrombotic Disorders

Oct 16, 2016 by in ONCOLOGY Comments Off on Thrombotic Disorders

Clinical scenario Recommendations Level of evidenceb Primary thromboprophylaxis Not recommended (including LMWH, warfarin, FFP) 1B Routine screening with coagulation studies or for thrombophilia not recommended 2C Thrombophilia screening can be…

read more

Hyperleukocytosis

Oct 16, 2016 by in ONCOLOGY Comments Off on Hyperleukocytosis

Disease Potential side effect Treatment Level of evidenceb Acute lymphoblastic leukemia Leukostasis Rapid initiation of chemotherapy 1A Hyperhydration 1C Consider leukapheresis for WBC >400–600 × 109/L if no delay in antileukemic chemotherapy…

read more

Tumor Lysis Syndrome

Oct 16, 2016 by in ONCOLOGY Comments Off on Tumor Lysis Syndrome

Laboratory tumor lysis syndrome (2 or more of the following occurring from 3 days prior up to 7 days after commencement of cytotoxic therapy)  Uric acid ≥8 mg/dL or 25…

read more

Transfusion Support

Oct 16, 2016 by in ONCOLOGY Comments Off on Transfusion Support

Clinical status Description Hemoglobin level for transfusion (g/dL) Level of evidencea Stable Asymptomatic, imminent marrow recovery <7 1C Vital sign changes Tachycardia, tachypnea, hypotension <8 1C Thrombocytopenia Recent or active…

read more

White Coat Hypertension and Target Organ Damage

Oct 16, 2016 by in ENDOCRINOLOGY Comments Off on White Coat Hypertension and Target Organ Damage

Fig. 5.1 Manifestations of subclinical cardiac organ damage related to hypertension: the association between left ventricular hypertrophy (LVH, upper panel) and diastolic dysfunction (lower panel) Several methods characterized by different…

read more
Get Clinical Tree app for offline access